270 related articles for article (PubMed ID: 10357952)
21. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
[TBL] [Abstract][Full Text] [Related]
22. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization.
Beckers NG; Laven JS; Eijkemans MJ; Fauser BC
Hum Reprod; 2000 Jan; 15(1):43-9. PubMed ID: 10611186
[TBL] [Abstract][Full Text] [Related]
23. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles.
Ubaldi F; Albano C; Peukert M; Riethmuller-Winzen H; Camus M; Smitz J; Van Steirteghem A; Devroey P
Hum Reprod; 1996 Jul; 11(7):1405-7. PubMed ID: 8671476
[TBL] [Abstract][Full Text] [Related]
24. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
25. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.
Kol S; Lightman A; Hillensjo T; Devroey P; Fauser B; Tarlatzis B; Mannaerts B; Itskovitz-Eldor J
Hum Reprod; 1999 Sep; 14(9):2242-4. PubMed ID: 10469687
[TBL] [Abstract][Full Text] [Related]
26. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone.
Claman P; Domingo M; Leader A
Hum Reprod; 1992 Apr; 7(4):487-9. PubMed ID: 1522190
[TBL] [Abstract][Full Text] [Related]
27. Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin-releasing hormone agonist/menotrophin in-vitro fertilization cycles.
Golan A; Herman A; Soffer Y; Bukovsky I; Caspi E; Ron-El R
Hum Reprod; 1993 Sep; 8(9):1372-5. PubMed ID: 8253920
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles.
Norman RJ; Warnes GM; Wang X; Kirby CA; Matthews CD
Hum Reprod; 1991 Feb; 6(2):206-13. PubMed ID: 1905309
[TBL] [Abstract][Full Text] [Related]
29. Addition of GnRH antagonist in cycles of poor responders undergoing IVF.
Akman MA; Erden HF; Tosun SB; Bayazit N; Aksoy E; Bahceci M
Hum Reprod; 2000 Oct; 15(10):2145-7. PubMed ID: 11006188
[TBL] [Abstract][Full Text] [Related]
30. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
31. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
Yıldız GA; Şükür YE; Ateş C; Aytaç R
Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
[TBL] [Abstract][Full Text] [Related]
32. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist.
Tavaniotou A; Albano C; Smitz J; Devroey P
Fertil Steril; 2002 Apr; 77(4):733-7. PubMed ID: 11937125
[TBL] [Abstract][Full Text] [Related]
33. Luteal phase characteristics following GnRH antagonist or agonist treatment - a comparative study.
Friedler S; Gilboa S; Schachter M; Raziel A; Strassburger D; Ron El R
Reprod Biomed Online; 2006 Jan; 12(1):27-32. PubMed ID: 16454930
[TBL] [Abstract][Full Text] [Related]
34. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study.
Olivennes F; Fanchin R; Bouchard P; Taïeb J; Selva J; Frydman R
Hum Reprod; 1995 Jun; 10(6):1382-6. PubMed ID: 7593501
[TBL] [Abstract][Full Text] [Related]
35. Outcome from consecutive in-vitro fertilization/intracytoplasmic sperm injection attempts in the final group treated with urinary gonadotrophins and the first group treated with recombinant follicle stimulating hormone.
Jacob S; Drudy L; Conroy R; Harrison RF
Hum Reprod; 1998 Jul; 13(7):1783-7. PubMed ID: 9740423
[TBL] [Abstract][Full Text] [Related]
36. Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study.
Vlaisavljevic V; Reljic M; Lovrec VG; Kovacic B
Reprod Biomed Online; 2003 Oct; 7(3):301-8. PubMed ID: 14653888
[TBL] [Abstract][Full Text] [Related]
37. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
[TBL] [Abstract][Full Text] [Related]
38. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility.
Felberbaum RE; Reissmann T; Küpker W; Bauer O; al Hasani S; Diedrich C; Diedrich K
Eur J Obstet Gynecol Reprod Biol; 1995 Aug; 61(2):151-5. PubMed ID: 7556837
[TBL] [Abstract][Full Text] [Related]
39. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.
Westergaard LG; Laursen SB; Andersen CY
Hum Reprod; 2000 May; 15(5):1003-8. PubMed ID: 10783342
[TBL] [Abstract][Full Text] [Related]
40. Progesterone change in the late follicular phase affects pregnancy rates both agonist and antagonist protocols in normoresponders: a case-controlled study in ICSI cycles.
Demir B; Kahyaoglu I; Guvenir A; Yerebasmaz N; Altinbas S; Dilbaz B; Dilbaz S; Mollamahmutoglu L
Gynecol Endocrinol; 2016; 32(5):361-5. PubMed ID: 26654315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
